K2 Principal Fund’s Trillium Therapeutics Inc. TRIL Stock Holding History

K2 Principal Fund’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45,000	Closed	-$790K	–	490
2021 Q3	$790K	Buy	+45,000	New	+$526K	0.06%	193
2017 Q3	–	Sell	-60,013	Closed	-$264K	–	423
2017 Q2	$264K	Buy	+60,013	New	+$332K	0.02%	301
2017 Q1	–	Sell	-16,239	Closed	-$92K	–	386
2016 Q4	$92K	Buy	+16,239	New	+$162K	0.01%	269
2016 Q3	–	Sell	-14,614	Closed	-$131K	–	333
2016 Q2	$131K	Buy	+14,614	New	+$152K	0.02%	231
2015 Q1	–	Sell	-19,783	Closed	-$178K	–	204
2014 Q4	$178K	Buy	+19,783	New	+$155K	0.04%	145

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

K2 Principal Fund's TRIL Position: Q4 2021 in Review

K2 Principal Fund sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 45,000 shares — an estimated $790K sold.

K2 Principal Fund first reported a position in TRIL in Q4 2014 and held it in 5 quarters. The position peaked at $790K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

K2 Principal Fund reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
K2 Principal Fund sold 45,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $790K.
K2 Principal Fund first reported a position in Trillium Therapeutics Inc. in Q4 2014 and held it in 5 quarters.
K2 Principal Fund's Trillium Therapeutics Inc. position peaked at $790K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on K2 Principal Fund's 13F filing for Q4 2021, filed 11 Feb 2022.